share_log

亨迪药业(301211.SZ):醋酸阿比特龙获得化学原料药上市申请批准通知书

Hengdi Pharmaceuticals (301211.SZ): Acetic acid abitron has obtained the approval notice for the market application of active pharmaceutical ingredient.

Gelonghui Finance ·  Jul 10 03:51

On July 10th, Gelonhui reported that Hendi Pharmaceuticals (301211.SZ) recently received the "Chemical Raw Materials Medicine Application Approval Notice" for abiraterone acetate issued by the National Medical Products Administration. The main purpose of abiraterone acetate is as a CYP17 inhibitor, which is suitable for treating previously treated metastatic castration-resistant prostate cancer patients with docetaxel-containing chemotherapy.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment